China Resources Pharmaceuticals: China Resources Pharmaceuticals Investment plans to publicly list and sell approximately 5.88% of its equity stake in Tianmai Biotech.

2026-03-22 08:29:36

China Resources Pharmaceutical announced that its wholly owned subsidiary, China Resources Pharmaceutical Investment, has initiated a potential sale of approximately 5.88% equity in Tianmai Biotechnology. The transaction will be publicly listed on the Shanghai United Assets and Equity Exchange, with an initial listing price of approximately RMB 510 million. Currently, China Resources Pharmaceutical Investment and its subsidiaries hold about 23.75% of Tianmai Biotechnology. The potential sale is independent and unrelated to the sale of certain shares of Tianmai Biotechnology by China Resources Pharmaceutical Investment and its subsidiaries.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.